153 related articles for article (PubMed ID: 24970929)
1. Complement, cold agglutinins, and therapy.
Berentsen S
Blood; 2014 Jun; 123(26):4010-2. PubMed ID: 24970929
[TBL] [Abstract][Full Text] [Related]
2. TNT003, an inhibitor of the serine protease C1s, prevents complement activation induced by cold agglutinins.
Shi J; Rose EL; Singh A; Hussain S; Stagliano NE; Parry GC; Panicker S
Blood; 2014 Jun; 123(26):4015-22. PubMed ID: 24695853
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of complement C1s improves severe hemolytic anemia in cold agglutinin disease: a first-in-human trial.
Jäger U; D'Sa S; Schörgenhofer C; Bartko J; Derhaschnig U; Sillaber C; Jilma-Stohlawetz P; Fillitz M; Schenk T; Patou G; Panicker S; Parry GC; Gilbert JC; Jilma B
Blood; 2019 Feb; 133(9):893-901. PubMed ID: 30559259
[TBL] [Abstract][Full Text] [Related]
4. The Anti-C1s Antibody TNT003 Prevents Complement Activation in the Skin Induced by Bullous Pemphigoid Autoantibodies.
Kasprick A; Holtsche MM; Rose EL; Hussain S; Schmidt E; Petersen F; Panicker S; Ludwig RJ
J Invest Dermatol; 2018 Feb; 138(2):458-461. PubMed ID: 28899686
[No Abstract] [Full Text] [Related]
5. Sutimlimab in Cold Agglutinin Disease.
Röth A; Barcellini W; D'Sa S; Miyakawa Y; Broome CM; Michel M; Kuter DJ; Jilma B; Tvedt THA; Fruebis J; Jiang X; Lin S; Reuter C; Morales-Arias J; Hobbs W; Berentsen S
N Engl J Med; 2021 Apr; 384(14):1323-1334. PubMed ID: 33826820
[TBL] [Abstract][Full Text] [Related]
6. Complement inhibitors to treat IgM-mediated autoimmune hemolysis.
Wouters D; Zeerleder S
Haematologica; 2015 Nov; 100(11):1388-95. PubMed ID: 26521297
[TBL] [Abstract][Full Text] [Related]
7. Uncoupling complement C1s activation from C1q binding in apoptotic cell phagocytosis and immunosuppressive capacity.
Colonna L; Parry GC; Panicker S; Elkon KB
Clin Immunol; 2016 Feb; 163():84-90. PubMed ID: 26769276
[TBL] [Abstract][Full Text] [Related]
8. Anti-C1s humanized monoclonal antibody SAR445088: A classical pathway complement inhibitor specific for the active form of C1s.
Simmons KT; Chan J; Hussain S; Rose EL; Markham K; Byun TS; Panicker S; Parry GC; Storek M
Clin Immunol; 2023 Jun; 251():109629. PubMed ID: 37149117
[TBL] [Abstract][Full Text] [Related]
9. A novel series of arylsulfonylthiophene-2-carboxamidine inhibitors of the complement component C1s.
Subasinghe NL; Travins JM; Ali F; Huang H; Ballentine SK; Marugán JJ; Khalil E; Hufnagel HR; Bone RF; DesJarlais RL; Crysler CS; Ninan N; Cummings MD; Molloy CJ; Tomczuk BE
Bioorg Med Chem Lett; 2006 Apr; 16(8):2200-4. PubMed ID: 16460935
[TBL] [Abstract][Full Text] [Related]
10. C1s Inhibition by BIVV009 (Sutimlimab) Prevents Complement-Enhanced Activation of Autoimmune Human B Cells In Vitro.
Nikitin PA; Rose EL; Byun TS; Parry GC; Panicker S
J Immunol; 2019 Feb; 202(4):1200-1209. PubMed ID: 30635392
[TBL] [Abstract][Full Text] [Related]
11. Complement C1s inhibition with sutimlimab results in durable response in cold agglutinin disease: CARDINAL study 1-year interim follow-up results.
Roth A; Barcellini W; D'Sa S; Miyakawa Y; Broome CM; Michel M; Kuter DJ; Jilma B; Tvedt THA; Weitz IC; Patel P; Jiang X; Reuter C; Su J; Shafer F; Lee M; Berentsen S
Haematologica; 2022 Jul; 107(7):1698-1702. PubMed ID: 35172561
[No Abstract] [Full Text] [Related]
12. Inhibition of complement C1s in patients with cold agglutinin disease: lessons learned from a named patient program.
Gelbenegger G; Schoergenhofer C; Derhaschnig U; Buchtele N; Sillaber C; Fillitz M; Schenk TM; D'Sa S; Cartwright R; Gilbert JC; Jilma B; Jaeger U
Blood Adv; 2020 Mar; 4(6):997-1005. PubMed ID: 32176765
[TBL] [Abstract][Full Text] [Related]
13. Activation of complement by cold agglutinins.
Kirschfink M; Knoblauch K; Roelcke D
Infusionsther Transfusionsmed; 1994 Dec; 21(6):405-9. PubMed ID: 7873919
[TBL] [Abstract][Full Text] [Related]
14. C1-inhibitor prevents PEG fractionation-induced, EDTA-resistant activation of mouse complement.
van den Berg CW; Aerts PC; van Dijk H
Mol Immunol; 1992 Mar; 29(3):363-9. PubMed ID: 1372956
[TBL] [Abstract][Full Text] [Related]
15. Antibody-mediates inhibition of human C1s and the classical complement pathway.
Carroll S; Georgiou G
Immunobiology; 2013 Aug; 218(8):1041-8. PubMed ID: 23434433
[TBL] [Abstract][Full Text] [Related]
16. Sutimlimab: First Approval.
Dhillon S
Drugs; 2022 May; 82(7):817-823. PubMed ID: 35412113
[TBL] [Abstract][Full Text] [Related]
17. Complement 1s is the serine protease that cleaves IGFBP-5 in human osteoarthritic joint fluid.
Busby WH; Yocum SA; Rowland M; Kellner D; Lazerwith S; Sverdrup F; Yates M; Radabaugh M; Clemmons DR
Osteoarthritis Cartilage; 2009 Apr; 17(4):547-55. PubMed ID: 18930415
[TBL] [Abstract][Full Text] [Related]
18. Blockade of HLA Antibody-Triggered Classical Complement Activation in Sera From Subjects Dosed With the Anti-C1s Monoclonal Antibody TNT009-Results from a Randomized First-in-Human Phase 1 Trial.
Mühlbacher J; Jilma B; Wahrmann M; Bartko J; Eskandary F; Schörgenhofer C; Schwameis M; Parry GC; Gilbert JC; Panicker S; Böhmig GA
Transplantation; 2017 Oct; 101(10):2410-2418. PubMed ID: 28926521
[TBL] [Abstract][Full Text] [Related]
19. [Accessory use of protease-inhibiting agents for disease remission in a patient with autoimmune hemolytic anemia associated with B-CLL].
Ijichi S; Sano Y; Une F; Maruyama I; Osame M
Rinsho Ketsueki; 1990 Feb; 31(2):219-23. PubMed ID: 2329684
[TBL] [Abstract][Full Text] [Related]
20. Complement Activation and Inhibition in Autoimmune Hemolytic Anemia: Focus on Cold Agglutinin Disease.
Berentsen S
Semin Hematol; 2018 Jul; 55(3):141-149. PubMed ID: 30032751
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
